MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

GV is set to exit customer data management platform Segment in an all-share deal that more than doubles its valuation from 18 months ago.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Merck Group, Bristol Myers-Squibb and Novo-backed cancer drug developer Galecto has filed to go public weeks after it last funding round.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Z Corporation has exited its 40% stake in crypto trading exchange TaoTao in an acquisition by SBI.

Nanopareil employs nanofibre membranes to separate chemical compounds for the purposes of purifying biopharmaceutical candidates.

Big Hit Entertainment, the Netmarble-backed talent management agency and record company, priced its initial public offering at the top of its range.

Vector Capital is acquiring the data integration platform developer three years after NTT invested and five after it secured a $1bn valuation.